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LIGHT MEDIATED DRUG DELIVERY USING PHOTOCAGED MOLECULES AND 
PHOTOSWITCHABLE PEPTIDES 
Deboleena Mitra 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University. 
  Virginia Commonwealth University, 2014.  
Advisor: Matthew C.T. Hartman, Associate Professor, Department of Chemistry 
There are many different types of cancer and various methods have been developed to treat them. 
Some of the methods of treatment are not highly specific and often patients suffer from various 
side effects. To make the treatment more specific the method of targeted therapy has evolved. One 
of the methods of targeted therapy that is highly selective as well as specific is the light mediated 
treatment of cancer. Photodynamic therapy and photochemical internalization fall under this 
category. Photodynamic therapy utilizes photosensitizers which operate only in the presence of 
light to form cytotoxic singlet oxygen. Light of a particular wavelength activates the 
photosensitizers and initiates the formation of singlet oxygen which eventually leads to cell death. 
However, this approach also has some drawbacks. There are problems associated with the light to 
drug administration time due to the slow uptake of the photosensitizers and the amount of 
molecular oxygen in the cancer cells is in low concentration for the generation of singlet oxygen. 
  
 
The method of light mediated targeted therapy that we have developed uses photocaged molecules 
and photoswitchable peptides that is devoid of the above drawbacks and is highly specific.  
In photocaging, a biologically active molecule is made inactive by the attachment of a 
photocleavable blocking group. On exposure to UV radiation the photocleavable entity is removed 
and the biologically active molecule is released. Using this concept we have designed a prodrug 
that consists of a cell impermeable hydrophilic molecule attached to a photocaged doxorubicin.  
The hydrophilic moiety makes the entire prodrug cell impermeable in the dark. Upon irradiation 
with UV light the photosensitive group is removed and cytotoxic doxorubicin is released at the 
tumor site. This concept has been further modified by attaching receptor binding molecules to the 
photocaged entity to increase its specificity. Folic acid has been attached to the photocaged 
doxorubicin that would interact with the folate receptors which are overexpressed in cancer cells. 
These targeting groups enable cancer cell selective drug delivery with light. 
A photoswitchable peptide has been used which, in the dark state is randomly coiled and cell 
impermeable but upon illumination becomes helical and cell permeable and can be used to deliver 
drugs into the cells. It has been established that the conformation of α helical peptides can be 
controlled by azobenzene photoswitches. So azobenzene linker with iodoacetamide group has been 
synthesized to link to the cysteine units of the synthesized peptides. It has also been established 
that an arginine patch developed on the surface of an impermeable protein will make it cell 
permeable as the positively charged arginines will interact with the heparin sulfate proteoglycans 
of the cell membrane. Upon illumination with UV light of suitable wavelength the azobenzene 
linker will change from a trans to a cis form and this will convert the randomly coiled cell 
impermeable peptide into an α helical permeable form. Thus a series of peptides have been 
  
 
designed with different arginine mutations which develop an arginine patch in the helical form. 
The change in their secondary structure has been studied with circular dichroism. Cell studies 
would be done in future with these peptides to verify their cell permeability. The method could 
potentially be used to deliver drugs into cells in presence of light. 
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CHAPTER 1 
 INTRODUCTION 
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1.1 Cancer and its Treatment 
Cancer is a disease of uncontrolled cell growth which eventually spreads to the different parts of 
the body. It is a leading cause of death worldwide. According to the data sheet published by 
International Agency for Research on Cancer 8.2 million people died of cancer in 2012 worldwide. 
There are many reasons for the cause of cancer. The external causes include chemicals, radiation, 
tobacco and infectious organisms while the internal causes are hormones, metabolic mutations, the 
immune system and the mutations that have been inherited genetically. There are many ways to 
treat cancer such as chemotherapy, radiation, surgery and targeted therapy. 
1.1.1 Chemotherapy  
Chemotherapy1,2,3  is the treatment of cancer with a drug or a combination of drugs to kill the 
rapidly growing cells. Chemotherapy is often used in combination with radiation or surgery. 
Chemotherapy used to shrink the tumor before radiation or surgery is called neo-adjuvant 
chemotherapy. Adjuvant chemotherapy involves treatment to destroy cancer cells that remain after 
surgery or radiation. 
1.1.1.1 Side Effects of Chemotherapy 
Chemotherapy destroys the healthy tissues also and that leads to the development of many side 
effects in patients4,5,6. It affects the healthy cells of the mouth and intestine, bone marrow and cells 
that are responsible for hair growth. Once these healthy cells get affected it leads to the emergence 
of a series of side effects that include nausea, fatigue, hair loss and reduced blood cell count. 
1.1.2 Targeted Therapy 
To overcome the side effects of chemotherapy and make the treatment more specific the method 
of targeted therapy7,8 has evolved. As the name suggests in targeted therapy the growth and spread 
of cancer is stopped by using drugs that specifically bind to a target cancerous cells. In this method 
 3 
 
there are many ways of delivering cytotoxic agents into cancer cells. Small molecular drugs are 
used in targeted therapy which can cross the plasma membrane and are often used to target proteins 
to affect their enzymatic activity or interaction with other substances. Imatinib mesylate (gleevec) 
is one such example of a small molecule that is used in targeted therapy and it is believed to affect 
the signaling pathways by targeting tyrosine kinase enzyme BCR-Abl that participates in signal 
transduction. Monoclonal antibodies are also used as a vehicle to deliver radioactive molecules or 
toxins inside the cancer cells.  Tositumomab (Bexxar) is a radioactive immunotoxin currently 
approved for therapy against certain types of non-Hodgkin lymphoma. Antibodies also can be 
designed to interact with the cell surface receptors to have a direct therapeutic effect. For example, 
Rituximab (rituxan) interacts with CD20 on the surface of mature B lymphocytes and triggers an 
immune response against the cancer cells. Vaccines are another means of targeted therapy which 
influence the immune system of the body to attach the cancer cells. Another method of targeted 
therapy that is highly selective as well as specific is the light mediated treatment of cancer. 
Photodynamic therapy and photochemical internalization fall under this category.   
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1.1.2.1 Photodynamic Therapy  
In Photodynamic therapy (PDT)9 the treatment consists of two components-a photosensitizer and 
a light of a particular wavelength that activates that photosensitizer10,11,12,13 . The photosensitizer 
is administered to the body using intravenous injection or by topical application on the affected 
region and then it gets absorbed by the cells and distributed all over the body. These 
photosensitizers stay in the cancer cells much longer than in the normal healthy cells. Usually after 
a time span of 24-72 hrs the normal healthy cells no longer retain the photosensitizer. After this 
time frame the tumor is exposed to irradiation of a particular wavelength that is specific for the 
photosensitizer. On absorption of the radiation the photosensitizer gets excited from the ground 
state (singlet state) to a triplet state. When it relaxes back to the singlet state it releases energy to 
the neighboring oxygen molecule. The oxygen absorbs the energy to form singlet oxygen that is 
toxic to the cells and finally leads to apoptosis. The process has been shown in Figure 1.1.1. It 
operates only in presence of light so it is highly selective. Photofrin is a FDA approved 
photosensitizing agent that is used for the treatment of esophageal cancer and non-small cell lung 
cancer. 
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Figure 1.1.1 Photodynamic Therapy 
                           
1.1.2.2 Disadvantages of Photodynamic Therapy 
 In photodynamic therapy the light that is used to activate the photosensitizers usually has moderate 
ability to penetrate into tissues. Thus the use of PDT is usually limited to regions that are easily 
penetrated by light such as the esophagus or tissues immediately below the skin. This limits the 
use of the technique to certain regions of the body. It cannot be used if cancer has metastasized. 
The effectiveness of this process also depends on the generation of singlet oxygen14. The amount 
of molecular oxygen available in cancer cells is usually not very high and hence the generation of 
singlet oxygen is also low. This slows down the process of apoptosis. Lastly there is much disparity 
in the light to drug administration time13 probably due to the slow uptake of the photosensitizers.  
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1.1.2.3 Photochemical Internalization 
Photochemical internalization (PCI)15,16,17 works on the same principle as photodynamic therapy 
with the only difference that an additional toxin is present. Certain macromolecular toxins are 
degraded in the endosomes before their release into the cells and this hinders the use of these 
molecules in cancer therapy. To improve their therapeutic use they are used with photosentizers 
that adhere to the endosomal membrane. Upon shining light of a particular wavelength these 
photosensitizers generate singlet oxygen that rupture the endosomal membrane and the toxin is 
released from the endosomes. This released toxin then causes cell death. The process has been 
shown in Figure 1.1.2. 
 
 
 
  
 
Figure 1.1.2 Photochemical Internalization 
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1.1.2.4 Disadvantages of Photochemical Internalization  
One of the drawbacks of photochemical internalization is that a toxin molecule has to be 
internalized via endosome first. This reduces the efficiency of this process. The low level of 
molecular oxygen in cancer cells also affects the process as the generation of singlet oxygen is 
dependent on the amount of molecular oxygen available. Lastly even in photochemical 
internalization there is much disparity in the light to drug administration time13. 
Thus to improve the light mediated targeted therapy some new drug delivery system needs to be 
developed that is devoid of the drawbacks present in PDT and PCI. This system should not depend 
on the availability of molecular oxygen in cancer cells and at the same time the disparity between 
light to drug administration time should not exist. 
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1.2 Photocaged Drug Delivery System 
1.2.1 Origin of Photocaged Molecules 
In photocaging18 a biologically active molecule is made inactive by the attachment of a 
photocleavable group. On exposure to UV radiation the photocleavable entity is removed and the 
biologically active molecule is released as shown in Figure 1.2.1. The term “caged”19 was first 
introduced by Joseph F. Hoffman in 1978 where he reported the development of “caged ATP”. 
His work showed for the first time how the caged molecules could be used to have a spatiotemporal 
control over biochemical experiments. The terminal phosphate group of ATP was attached to 
photolabile groups such as 2-Nitrobenzyl and 1-(2-)nitrophenylethyl. The caged molecule in 
absence of radiation was not hydrolyzed by an enzyme as it was not a substrate for that enzyme. 
Upon irradiation at 340nm the photolabile group was removed and ATP was released. This 
released ATP was a substrate for the enzyme and was quickly hydrolyzed by it. Since then this 
idea of photocages has been used extensively to control the activity of many biological molecules. 
It is an irreversible turning on of the activity of a molecule.  
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Figure 1.2.1 Release of Active Drug from Inactive Photocaged drug on exposure to UV 
radiation 
 
 
  
 
1.2.1 Types of Photocages 
There are many photo-labile or photocaging groups that are available18. The most commonly used 
photocage molecule is o-nitrobenzyl group. The reason behind its frequent use is the fact that it is 
easily synthesized and can be easily incorporated in any molecule. Typically the compound used 
is the nitroveratryl cage which has an m- and p- (-OCH3) groups in its structure (Figure1.2.2). 
These electron donating groups shift the absorption maximum to a longer wavelength such as 365 
nm. One nice application of this nitroveratryl group has been used by Lawrence and coworkers in 
the photocaging of ecdysone20. Caged ecdysone would help to control gene expression with light. 
A luciferase reporter controlled by ecdysone system was introduced in mammalian cells and the 
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expression of luciferase was studied in the presence and absence of light. Upon irradiation when 
the natural ecdysone molecule was released it led to about 60% of luciferase expression. 
 
 
 
 
Figure 1.2.2 Nitroveratryl group: Typically used nitroveratryl group in photocaging with (-
OCH3) groups at meta and para positions 
 
 
The other type of photocaged molecules that are commonly used are the derivatives of coumarin 
(Figure 1.2.3). Coumarin has been used to develop a caged mRNA that has been used by Roger 
Tsien and Okamato to control the gene expression in zebrafish embryos21,22. Wen-Hong Li and 
coworkers have developed caged coumarins that showed 200 fold more fluorescence enhancement 
after being photolysed by UV23.  
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Figure 1.2.3 Coumarin Derivative 
 
 
 
The photocaging molecules provide an irreversible spatiotemporal control over some biological 
systems. It would be good to have a reversible control over a biological system using light.  
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1.3 Photoswitches in Drug Delivery   
Photoswitches24,25 are molecules that switch reversibly between two different conformations when 
exposed to light of a particular wavelength. They help to attain several cycles of active and inactive 
state and it is usually seen in ring-opening /closing and isomerization reactions. This behavior of 
the photoswitches is effectively used in controlling the spatiotemporal behavior of many 
biomolecules. Some of the most commonly used photoswitches are azobenzenes, stilbenes and 
spiropyrans26,27,28,29 . 
1.3.1 Azobenzene Molecule as a Photoswitch 
Azobenzene is one of the most commonly used photoswitches30,31,32,33,34,35,36 in biological studies. 
It exists in two photoisomeric forms–the trans form and the cis form. The trans form of azobenzene 
switches to the cis form when exposed to a radiation of 340 nm. The cis form thermally relaxes 
back to the trans form or upon irradiation with light of 450 nm. This has been shown in Figure 
1.3.1. 
 
 
Figure 1.3.1 Azobenzene Photoswitch 
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The trans form of the azobenzene is planar37 and has been found to be more stable than the bent 
conformation adopted by the cis form by 10-12 kcal/mol. The trans form is also the dominant 
isomer in the dark state. 
The time needed for the unmodified cis azobenzene to thermally relax to the trans form is a few 
days at room temperature. So if this azobenzene photoswitch is to be incorporated in any biological 
system and a faster photoswitch is needed then this molecule needs to be modified. Much work 
has been done to modify the azobenzene with different substituents. 
The wavelength used to photoswitch the azobenzene molecule is in the UV range at 340 nm. At 
this wavelength light does not have a good tissue penetration ability. To improve the tissue 
penetration ability   various substituents have been introduced in the azobenzene ring that would 
red shift the absorption maximum of the compound. This shift towards higher wavelength would 
improve the tissue penetration.  
1.3.2 Modification of Wavelength of Azobenzene Photoswitch 
The unmodified azobenzene photoswitch undergoes photoisomerization38,39 in the UV region. To 
make it less harmful for the tissues during in vivo studies, substituents have to be incorporated in 
the azobenzene rings to red shift the absorption maximum. This red shift of wavelength would also 
improve the tissue penetration ability that was a drawback of the UV light used to photoswitch 
unmodified azobenzene. The nature and position of the substituents40 on the benzene rings affect 
the red shift. The presence of electron donating group at the para position of one phenyl ring and 
the presence of electron accepting group at the para position of the other phenyl ring red shifts the 
absorption maximum of the azobenzene ring to a great extent. The excited state for the 
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photoisomerization is charged and hence more dipolar than the ground state. When electron 
donating and electron accepting groups are present in these molecules at para positions it helps in 
the charge distribution of the excited state by resonance and this reduces the activation energy 
barrier. So a higher wavelength of radiation is required to switch the molecule from trans isomeric 
form to the cis isomeric form. An example of such azobenzene derivative is shown in Figure 1.3.2 
where there is an electron donating –OCH3 group at the para position of one ring and an electron 
accepting –NO2 group in the other ring. 
 
 
Figure 1.3.2 4/-Methoxy-4-nitro-azobenzene 
 
1.3.3 Modification of Azobenzene Relaxation Rate 
The relaxation rates from the cis to the trans form of azobenzene molecule is of prime importance 
as that would decide the type of study these azobenzene photoswitches would help to monitor. If 
a fast biochemical reaction needs to be monitored that involves a pulsed conformational change 
then a short lived cis isomer with a fast relaxation time is desired.  Kamei and group have 
developed the azobenzene photoswitch 4-(dimethylamino)-4/amidoazobenzene that has a 
relaxation time of around 0.1 ms. They have introduced this photoswitch into a single stranded 
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DNA. On the other hand if a reaction needs to be sustained over several hours then an azobenzene 
derivative with a longer relaxation time needs to be used. 
There are many factors that affect the cis to trans relaxation rate of azobenzene. Some of these 
factors are the solvents41 used, pH of the solvent42 and the nature of substituents on the phenyl 
rings. The thermal transition state is dipolar in nature. Polar solvents would stabilize the dipolar 
transition state and reduce its activation barrier thus making the thermal transition faster. At a 
lower pH the azobenzene nitrogens would be protonated thus stabilizing the transition state and 
accelerating the reaction. 
The nature of the substituents present in the phenyl ring also influences the transition rate. The 
presence of groups that resonance stabilize the thermal transition state reduces the activation 
energy barrier and increases the rate of thermal relaxation. The dipolar nature of the transition state 
for the excited state is similar to that of the thermal relaxation. So substituents that red shift the 
absorption maximum also accelerate the thermal relaxation. Woolley and coworkers have 
introduced many substituents at the para position of azobenzene molecule and studied the shift of 
their absorption maximum and change in thermal relaxation rates43. The presence of an alkyl 
carbon atom at the para position makes the absorption maximum to be 342 nm with a half-life of 
43 hours for thermal relaxation. The replacement of this carbon atom with an amide group red 
shifts the absorption maximum to 366 nm and the half-life of thermal relaxation changes to 12 
minutes. The presence of a urea substituent at the para position changes the absorption maximum 
to 382 nm and the thermal relaxation becomes extremely fast with a half-life of 80 seconds. The 
structures of these compounds have been shown in Figure 1.3.3.Thus by introducing different 
substituents at the para position the absorption maximum and thermal relaxation of azobenzene 
photoswitches can be controlled. 
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Figure 1.3.3 Azobenzene Derivative with substituents: Azobenzene derivatives with carbon 
substituent (A), amide substituent (B) and urea substituent (C) at para position 
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1.3.4 Use of Azobenzene Photoswitches in Controlling Peptide Conformations 
 
Various derivatives of azobenzene molecules have been used to control the conformation of 
peptides44,45. Peptides form an integral part of many biological systems and having a 
spatiotemporal control over its conformation would help to modulate and study many biological 
processes. 
Schutt and group have cyclized a heptapeptide containing the RGD sequence (Arg-Gly-Asp) with 
4-aminomethylphenylazobenzouic acid (AMPB)46,47. It is known that the RGD sequence interacts 
with αVβ3 integrin- a cell surface receptor which mediates the adhesion between cells and the 
extracellular matrix48.  The AMPB bound RGD peptides binds to the αVβ3 with higher affinity 
only when the isomer is in the trans form. This was a control over the attachment of RGD sequence 
with αVβ3 using AMPB. 
Woolley and coworkers have also used various derivatives of azobenzene to control the secondary 
structure of peptides by attaching the  linker to the peptides through cysteines placed at (i, i+4), (i, 
i+7) or (i, i+11) positions49,50. Molecular modelling helped them to decide which isomeric form of 
the linker was a better fit at these positions. They developed the azobenzene linker 3,3/-
bis(sulfonato)-4,4/-bis(chloroacetamido)azobenzene (BSBCA)51. The end to end distance of the 
trans form of this linker would fit well at the (i, i+11) positions of a peptide making it helical while 
the length of the cis form was not compatible with this spacing. So on exposure to UV radiation 
when the trans isomer photoswitched to the cis form the helicity of the peptide decreased. 
Thus much work has been done by researchers to use azobenzene derivatives in controlling the 
conformation of peptides. 
 18 
 
1.4 Cell Penetrating Peptides in Drug Delivery 
Cell penetrating peptides (CPP)52,53,54,55,56,57 are emerging as an important means of delivery of 
different types of cargo like ribonucleic acids, quantum dots, nano particles or insoluble dugs into 
the cells. The transport of the insoluble drugs has made the CPP more important in therapeutic 
studies. Tat58, penetratin59 and nona-arginine60 are examples of some cell penetrating peptides. 
CPP undergo internalization by endocytosis or by interacting with the cell surface glycans. TAT 
undergoes internalization by endocytosis whereas the positively charged arginine of nona-arginine 
interacts with the heparin sulfate proteoglycans of the cell membrane and enters the cell. 
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  CHAPTER 2 
PHOTOCAGED PERMEABILITY- 
A NEW STRATEGY FOR DRUG RELEASE 
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2.1 Introduction 
Oﬀ-target toxicity plagues conventional cancer chemotherapy. One strategy to enhance selectivity of anti-
cancer drugs involves un-masking the cytotoxicity of a molecule in the vicinity of the tumor61. This type 
of activation can be mediated by enzymes61,62, changes in pH63, or exogenous factors such as 
temperature64 or light65,66,67. Light is an ideal external stimulus since it provides a broad range of 
adjustable parameters68 that can be optimized for biological compliance. Several approaches that 
use light for biomolecular activation have been reported69,70,71,72,73. One established method to enable 
selectivity of drug action using light is photodynamic therapy (PDT). In PDT,74,9 light activation of a 
photosensitizer generates cytotoxic singlet oxygen killing only illuminated cells. PDT is currently 
used in several types of malignancies including skin, lung, esophageal, bladder, head and neck, and 
prostate cancer. A related strategy, photochemical internalization,75,15 also uses photosensitizers. In 
this case, the photosensitizers are used to release macromolecular cytotoxins from endosomes, 
enabling their entry into the cytosol. However, these approaches suﬀer from disadvantages,76 including 
unpredictable drug uptake rates, the limited diﬀusion and lifetime of 1O2, and the requirement for 
moderate levels of O2 which may not always be available in the tumor environment. 
In this communication, we report a new light-targeted drug delivery system, which operates 
independently of the creation of 1O2. The basis of the system is the attachment of a cell 
impermeable small molecule to a drug via a linker that can be removed in presence of light, 
allowing cellular entry (Fig. 2.1). We call this new strategy photocaged permeability (PCP). 
More speciﬁcally, we report the controlled release of the anti- cancer drug, doxorubicin (Dox) 
(Fig. 2), upon illumination. To prevent entry of Dox in the dark we attached Dox to EDANS (Fig. 
2), a small ﬂuorophore, chosen because it contains a sulfonic acid moiety known to hinder cellular 
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entry.77 To connect Dox to EDANS we utilized a light-cleavable nitroveratryl (1) linker.78 The 
nitroveratryl moiety has been used previously as a photocaging group for a wide variety of 
biomolecules. 
 
 
Figure 2.1. 1 Photocaged Permeability Strategy for Drug Delivery  
 
 
 
Figure 2.1. 2  a). The anticancer drug doxorubicin. b). Cell-impermeable EDANS  
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2.2. Materials and Methods:  
2.2.1: Synthesis of Dox-EDANS Drug Conjugate: 
The synthesis (Scheme 1) began with commercially available nitroveratryl carboxylic acid (1). 
The N-hydroxy succinimide ester was prepared followed by coupling with propargylamine to give 
amide (1). This compound was converted to the p-nitrophenyl carbonate which was then treated 
with doxorubicin to generate photocaged doxorubicin carbamate (3). EDANS was coupled with 
azido benzoic acid (5) and was ﬁnally attached to the photocage using click chemistry to generate 
the ﬁnal Dox-EDANS conjugate (6). 
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Scheme 2. 1: Synthesis of photocaged-cell impermeable drug conjugate. Reagents and conditions: 
(a) NHS, EDC-HCl; (b) propargylamine, Et3N; 
(c) bis p-nitrophenylcarbonate, Et3N; (d) doxorubicin-HCl, Et3N; (e) NHS, EDC-HCl; (f) 
EDANS, EtN(iPr)2; (g) CuSO4·5H2O, sodium ascorbate, tris-(benzyltriazolylmethyl)amine, 
DMSO : water (1 : 1). 
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2.2.2 Cell Studies: 
The Esophageal cancer cell line (JH-EsoAd1) was cultured at 37oC and in a humidified atmosphere 
of 5% CO2 in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS). For 96 well 
plate experiments, the JH-EsoAd1 cells were seeded at 4450 cells/well in 100uL of media in 96 
well plates; experiments were carried out one day after seeding. MTT assays were analyzed using 
a Bio-Tex µQuant plate reader at 562 nm. FACS was performed BD FACS Aria II using BD FACS 
Diva software at the VCU Flow Cytometry Core Facility. A minimum of 20,000 cells within the 
gated region were analyzed. Confocal microscopy images were acquired at room temperature with 
a Leica confocal laser scanning microscope. 
2.2.2.1 Illumination Time-Dependent Toxicity: 
JH-EsoAd1 cells were treated with media alone, media supplemented with EDANS (20 µM), or 
media supplemented with Dox-EDANS (20 µM) in a 96 well clear-bottom, opaque plate. Cells 
were exposed to light (9 mW/cm2) for various times (0-40 min) regulated by an aluminum foil 
mask. During the experiment the plate was kept in ice to reduce the heating by the UV lamp.  After 
the lamp was turned off, the plate 
was covered with foil and placed at room temperature for an additional 80 min. The media was 
removed, and the cells were thoroughly washed with PBS (3x, 200µL); then 200 µL of fresh media 
was added to each well. The plates were incubated for 72 hours at 37oC, following which the media 
was removed and 100 µL of MTT (2mg/ml) in phosphate buffered saline (PBS) was added to each 
well. After 3 hours, the MTT solution was removed and replaced with 100 µL of DMSO. The 
absorbance at 562 nm was analyzed via a plate reader. 
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2.2.2.2: Concentration Dependent Cell Viability Studies: 
JH-EsoAd1 cells were treated with media supplemented with various concentrations of 
doxorubicin (0-6.4 µM) or Dox-EDANS (6) (0-16 uM) in a 96 well clear-bottom, opaque plate. 
Control wells were covered with aluminum foil while the remaining wells were exposed UV light 
(9 mW/cm2) for 20 min. The plate was kept in ice during light exposure in order to minimize the 
heating. After irradiation, the plate was kept at rt in the dark for another 100 minutes. The cells 
were washed and treated as above (time dependent toxicity experiments) to determine viability via 
the MTT assay. 
2.2.2.3: Flow cytometry analysis of permeability: 
JH-EsoAd1 cells were seeded at 150,000 cells/well in 1.5 mL of media in 6 well plates. The cells 
were treated with media alone or media supplemented with 10 µM of EDANS-Dox (6). The plate 
was placed on ice, and the light treated cells were exposed to UV light (9 mW/cm2) for 20 minutes. 
Following the light exposure the plates were kept at room temperature for 100 minutes. Then, the 
cells were washed with sterile PBS and trypsinized.  For quantification of Dox fluorescence, 
treated cells were trypsinized, harvested, and washed with PBS at approximately 1x106 cells/mL. 
Pellets were fixed for 15 min at 37oC with 3% paraformaldehyde in PBS. Samples were washed 
thoroughly with PBS, resuspended in PBS and analyzed by flow cytometry. 
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2.2.2.4: Confocal microscopic analysis of permeability: 
JH-EsoAd1 cells were seeded at 30,000 cells/well on 4 well glass chamber slides, and were treated 
as above (Flow cytometry analysis). The cells were treated with media alone or media 
supplemented with 10 µM of EDANS-Dox (6). The plate was placed on ice, and the light treated 
cells were exposed to UV light (9 mW/cm2) for 20 minutes. Following the light exposure the 
plates were kept at room temperature for 100 minutes. The cells were washed extensively with 
PBS and fixed for 15 min at 37oC with 3% paraformaldehyde in PBS. Slides were rinsed, dried 
and mounted under coverslips using Vectashield mounting media (Vector Laboratories, Inc.). 
 
 
 
 
 
2.2.3: UV Lamp: 
The UV lamp used in all studies consisted of a simple aquarium light fixture containing two Philips 
PL-S 9w/2P BLB bulbs. The intensity of the lamp was measured in the lab of Prof. M. Bertino 
(VCU) with the help of Michael Foussekis (VCU). The intensity was measured at different 
distances from the lamp and was found to decrease with increasing distance from the lamp. 
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Table 2.2. 1 Measurement of Intensity of UV Lamp 
Distance of Photodetector  
from UV Lamp 
  Intensity of Lamp 
  (mWatts/cm
2
) 
 Exactly Below lamp              9 
 1 inch below lamp            6.6 
 3 inches below lamp                 3.9 
 4 inches below lamp            2.8 
Where diameter of the detector window was 9mm 
 
2.3 Results 
2.3.1: Effect of Light on the IC50 of Doxorubicin 
 The dox-EDANS drug conjugate that we would use to validate our hypothesis has doxorubicin in 
it. It was important to see if the presence of the UV light affects the IC50 of doxorubicin itself in 
Jh-EsoAd1 cells. The conclusion of this assay would help us compare the cytotoxicity induced in 
JhesoAd1 cells by the Dox-EDANS drug conjugate under dark and light conditions with that 
induced by doxorubicin itself under such conditions. In order to determine the effect of light on 
cytotoxicity of doxorubicin, we treated the Jh-EsoAd1 cells with (0.025uM, .05 µM, 0.1 µM, 0.25 
µM, 0.4 µM, 0.8 µM, 1.6 µM, 3.2 µM and 6.4 µM) of doxorubicin in the presence and absence of 
UV lamp. The fraction of surviving cells was evaluated using the absorbance of the formazan 
product of MTT reduction.   The IC50 plot of the JH-EsoAd1 cells with doxorubicin in light and 
dark conditions is shown in Figure 2.3.1. The cytotoxicity in the presence of UV light as shown 
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by the red curve is similar to that under dark conditions as shown by the blue curve respectively 
in the Figure 2.3.1. Therefore, doxorubicin is cytotoxic to the cells to the same extent under 
illumination or in darkness. The value of IC50 remains 1.0 ±0.4 µM under both conditions. 
 
 
 
 
 
Figure 2.3.1 IC50 of Doxorubicin in Jh-EaoAd1 Cells: IC50 of Doxorubicin in Jh-EsoAd1 cells 
in the presence of UV light (Red Curve) and in Dark (Blue Curve) conditions.  
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2.3.2: Effect of EDANS in Jh-EsoAd1 Cells under Light and Dark Conditions: 
 
Since our conjugate also contain EDANS, we needed to show that it did not contribute to the 
cytotoxicity in the presence of light.  The cells were treated with 20µM of EDANS and the assay 
was completed following the protocol mentioned in section 2.2.2.1. The effect of EDANS on the 
Jh-EsoAd1 cells over this time period has been shown in Figure 2.3.2 which is an average of three 
individual experiments. EDANS does not affect the cells prior to 20 minutes in the light and then 
the cell viability decreases thereafter. Under the dark conditions EDANS is not cytotoxic to the 
cells over the entire time period.  
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Figure 2.3.2 Effect of EDANS in Jh-EsoAd1 Cells:  Effect of EDANS on treatment with Jh-
EsoAd1 cells in the presence of UV light (blue curve) and in dark (red curve). 
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2.3.3: Light Dependent Cytotoxicity of Dox-EDANS on Jh-EsoAd1 Cells 
 
We proceeded to investigate the extent to which the release of Dox with light would lead to enhanced 
cellular toxicity. Indeed, increased illumination lead to decreased survival as measured by an 
MTT assay as shown in Figure 2.3.5. The cells with the Dox-EDANS drug were exposed to UV light for 
1min, 5 mins, 10 mins, 20 mins and 40 mins respectively.  As the illumination time increased the cellular 
toxicity increased and the cellular viability almost reduced to 20 at the 40th minute as shown in the curve with 
solid diamonds in the figure 2.3.3. Whereas the Dox-EDANS conjugate is almost non toxic to the cells under 
the dark conditions as evident from the dotted curve with open squares in the same figure. This effect was not 
seen with doxorubicin and EDANS and clearly the cellular cytotoxicity is arising from the light controlled 
release of doxorubicin from the Dox-EDANS drug conjugate. 
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Figure 2.3.3 Light-dependent cytotoxicity of EDANS-Dox: Cells were treated with 
10 mM of Dox-EDANS with (solid diamonds) or without (open squares) light for the 
speciﬁed times.  
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2.3.3 Concentration Dependent Cytotoxicity Study of Dox-EDANS on Jh-ESoAd1 Cells 
 
The Jh-EsoAd1 cells were treated with Dox-EDANS drug at concentrations of 0.02 µM to 16 µM 
under illumination and dark conditions. The cells were exposed to UV light for 20 minutes and 
then kept incubated with the drug as mentioned in the section 2.2.2.2 (Concentration dependent 
Cell Viability Studies).  From Figure 2.3.4 it is clearly evident that cytotoxicity is induced in the 
presence of the UV light (black diamonds) whereas in the dark (open squares) cell viability is 
almost intact. The IC50 has been found to be 1.6 ± 1.0 µM  
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Figure 2.3.4 Concentration-dependent IC50 of EDANS-Dox: Cells were treated with EDANS-
Dox at various concentrations in the dark (open squares) or with UV light for 20 min (black 
diamonds). 
  
 
  
 35 
 
2.3.4 FACS and Confocal Studies to Study Cell Permeability of Dox-EDANS Drug 
 
We then investigated whether the attachment of EDANS to Dox via the veratryl linker would enable 
drug delivery. JH-EsoAd1 cells were incubated with Dox-EDANS or untreated with the drug in the 
dark or with illumination. Cell permeability was measured with ﬂow cytometry; upon illumination a 
signiﬁcant enhancement of cellular Dox ﬂuorescence was observed (Figures: 2.3.5; 2.3.6 and 2.3.7). 
From Figure 2.3.5 it is clearly evident that the cells without the drug under light (red curve) or dark 
(blue) conditions do not show enhanced fluorescence. In the presence of the drug under light (green 
curve) the fluorescence intensity is enhanced compared to the dark condition (orange curve). A 
Representative dot plot of the relative fluorescence intensity of EDANS-DOX in Light or Dark has 
been shown in Figure 2.3.6 where the gate shown in the left panel (A) was used to derive the % 
Fluorescence data shown in the right panel (B). The Dox fluorescence quantified in the right panel 
(B) clearly indicates the enhanced % Fluorescence of Dox in the presence of UV light.  
 
 
 36 
 
 
 
 
 
 
 
Figure 2.3.5 Flow cytometry of JH-EsoAd1 cells with and without EDANS-Dox: The ﬂow 
cytometry histogram displays the relative ﬂuorescence intensity of untreated controls in the dark 
(blue) or light (red) or JH-EsoAd1 cells treated with EDANS-Dox in the dark (orange) or light 
(green). 
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Figure 2.3.6 Relative fluorescence intensity of EDANS-DOX in Light or Dark: Flow 
cytometry analysis of EDANS-Dox with JH-EsoAd1 cells were performed in the dark and upon 
illumination (9.0 mW/cm2) for 20 min. Left Panel (A): Representative dot plot of the relative 
fluorescence intensity of EDANS-DOX in Light or Dark. The gate shown was used to derive the 
% Fluorescence data shown in the right panel. Right Panel (B): Quantification of DOX 
fluorescence for the indicated treatment conditions. Data are representative of two independent 
experiments, N=9. 
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This enhancement of fluorescence was mirrored in confocal studies with the same cell line (Figure 
2.3.11); only light-treated cells show signiﬁcant Dox ﬂuorescence in the nucleus, where it is known 
to accumulate. 
 
 
 
 
Figure 2.3.7 Confocal images of JHEsoAd1 cells with and without EDANS-Dox: These are 
representative confocal images of JHEsoAd1 cells treated with EDANS-Dox in the dark or light. 
The red channel shows Dox ﬂuorescence, the gray channel is a DIC image, and the overlay 
represents the cellular localization of Dox ﬂuorescence. Data are representative of two independent 
experiments of N=9. 
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2.4: Discussion  
We have developed a new and eﬃcient strategy for drug release based on photocaged permeability 
(PCP). In this first report, we have focused on applying PCP to the light-stimulated delivery of 
Dox into esophageal adenocarcinoma cells.  
From the FACS studies (Figures 2.3.5, 2.3.6,) it is clearly evident that the Dox-EDANS conjugate 
does not enter the cells in dark. In the presence of light the nitroveratryl group is removed and the 
doxorubicin is released and is cell permeable. Doxorubicin upon entering the cells interacts with 
the DNA in the nucleus. The localization of doxorubicin in the nucleus in the presence of light is 
evident from Figure 2.3.7. 
In principle, the PCP approach could be applied to any small, cell permeable molecule that has a 
free amine, hydroxyl, or carboxylic acid group for attachment of the veratryl-EDANS molecule. 
Further experiments will focus on use of other light-scissile linkers that can operate at longer 
wavelengths that are able to penetrate farther into tissues, as well as the use of other molecules that 
block permeability. 
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CHAPTER 3 
 PHOTOCAGED PERMEABILITY (PCP) 
IN RECEPTOR MEDIATED DRUG DELIVERY 
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3.1: Introduction:  
Targeted therapies are being used to treat different types of diseases in order to prevent various 
side effects that are part of the conventional treatments. The photocaged permeability (PCP) 
concept that has been introduced in chapter 2 is specific in terms of its light controlled drug release. 
To make this method dually specific we have tried to modify the conjugates such that a receptor 
binding molecule is attached to the photocaged entity. The receptor binding molecule would be 
specific for a particular receptor and once the drug conjugate gets internalized then upon shining 
light the photocaged molecule will be removed releasing the cytotoxic doxorubicin leading to 
death.  
Targeted therapy is being widely used in cancer treatment where the overexpressed receptors on 
cancer cells are being used for drug delivery.  Folate receptor79,80,81,82,83 is one of the receptors that 
are overexpressed in cancer cells. Much work has been done to develop folate-drug conjugates 
that are taken up by cancer cells through the folate receptors 84. Radioactive imaging agents have 
also been internalized using the folate receptors 85. The drug conjugate that we have developed has 
the photocaged molecule attached to folic acid (Dox-Folate conjugate) as shown in Figure 3.1.1. 
The folic acid of the drug conjugate would interact with the folate receptor and be internalized via 
endocytosis. The drug is not released until the drug conjugate is exposed to light.  
Beyond folic acid, this strategy would open the doors to the use of photocaged technologies 
with other cell targeting molecules such as DUPA (2-[3-(1, 3-dicarboxy propyl)-ureido]) that binds 
to PSMA (prostate specific membrane antigen)86 which is overexpressed in prostate cancer cells.  
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Figure 3.1.1 Structure of the Photocaged Doxorubicin-Folate (Dox-Folate) Conjugate   
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3.2 Materials and Methods 
3.2.1 Dox-Folate Drug Conjugate 
The Dox-Folate conjugate shown in Figure 3.1.1 has been used for the study.  
 
3.2.2 Solubility and Concentration of the Doxorubicin-Folic Acid Drug Conjugate 
 
The Dox-Folate conjugate was initially dissolved in DMSO and it was precipitating. To overcome 
this problem 4 µL of 1 (N) acetic acid was added to a 20 µL solution of the drug conjugate in 
DMSO. This changed the pH of the solution from 10.5 to 6.5 as indicated by the pH paper and the 
precipitation of the drug conjugate stopped. So for the cell studies the drug conjugate was dissolved 
in DMSO with 1(N) acetic acid.  
The concentration of the doxorubicin-folic acid drug conjugate was measured on nano drop using 
molar extinction coefficient of 11500 for doxorubicin in DMSO at 480nm. 
 
3.2.2 Cell Studies 
The initial experiments were done with FRα-null (R2) and FRα-(RT16) Chinese hamster cells 
(CHO)87,88,89 which were obtained from Prof. Larry H. Matherly, Department of Pharmacology, 
School of Medicine, Wayne State University. The R2 cells were cultured in α-minimal essential 
medium (MEM) supplemented with 10% fetal bovine serum (USA Origin, heat inactivated), 
glutamine and penicillin-streptomycin solution. The RT16 cells were cultured in α-MEM medium 
supplemented with 10% fetal bovine serum (USA Origin, heat inactivated), glutamine, penicillin-
streptomycin solution and G418 (1.5 mg/mL). For the cytotoxic assays the R2 cells were cultured 
in RPMI 1640 with 10% dialyzed fetal bovine serum (USA Origin, heat inactivated), glutamine 
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and penicillin-streptomycin solution for 2 passages before the cytotoxic experiments. Similarly the 
RT16 cells were cultured in folate-free RPMI media supplemented with 10% dialyzed fetal bovine 
serum, glutamine, penicillin –streptomycin solution and G418 (1.5 mg/mL) for two passages prior 
to the cytotoxic experiments. The other cell line used for the experiments were KB-3-1 cells 
obtained from Prof. Jamal Zweit, Department of Radiology, Virginia Commonwealth University. 
These cells were cultured in Dulbecco’s minimum essential medium (DMEM) supplemented with 
10% fetal bovine serum and penicillin-streptomycin solution. All the cell cultures were carried out 
in a humidified atmosphere of 5 % CO2. 
For 96 well plate experiments, the cells were seeded at 5000 cells/well in 100uL of media in 96 
well plates; experiments were carried out one day after seeding. MTT assays were analyzed using 
a Bio-Tex µQuant plate reader at 562 nm. FACS was performed BD FACS Aria II using BD FACS 
Diva software at the VCU Flow Cytometry Core Facility. A minimum of 20,000 cells within the 
gated region were analyzed. Confocal microscopy images were acquired at room temperature with 
a Leica confocal laser scanning microscope. 
The UV lamp used in all studies consisted of a simple aquarium light fixture containing two Philips 
PL-S 9w/2P BLB bulbs placed on top of the surface of the plate. 
 
3.2.2.1 Concentration Time point assay:  
The cells were treated with media alone in a 96 well clear-bottom, opaque plate. Cells were 
exposed to light (9 mW/cm2) for various times (0-120 mins) regulated by an aluminum foil mask. 
During the experiment the plate was kept in ice to reduce the heating by the UV lamp. The media 
was removed, and the cells were thoroughly washed with PBS (3x); then 200 µL of fresh media 
was added to each well. The plates were incubated for 72 hours at 37oC, following which the media 
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was removed and 100 µL of MTT (2mg/ml) in phosphate buffered saline (PBS) was added to each 
well. After 3 hours, the MTT solution was removed and replaced with 100 µL of DMSO. The 
absorbance at 562 nm was analyzed via a plate reader. 
 
3.2.2.2 Flow Cytometry analysis 
The cells were seeded at 200,000 cells/well in 1.5 mL of media in 6 well plates. The cells were 
treated with media alone, media with 1 µM of Dox-Folate  conjugate (4), media with 1 µM of 
doxorubicin, media with folic acid (20 µM) + 1 µM of drug conjugate or media with 1 µM of 
doxorubicin + folic Acid (20 µM) at various time points . For the inhibitory studies in presence of 
folic acid at first, the cells were pre -incubated with 20 µM of folic acid for an hour and then the 
drug conjugate or doxorubicin was added to the wells and incubated for time period of 30 minutes, 
3 hours and 24 hours. Then, at the end of each time point the cells were washed with sterile PBS 
and trypsinized. The trypsinized cells were centrifuged and resuspended in PBS supplemented 
with 10% FBS at 37oC and analyzed by flow cytometry. The fluorescence of doxorubicin was used 
to monitor the cell permeability of the drug. The cells were treated with media alone or media 
supplemented with 1 µM Doxorubicin-Folic acid conjugate (4). The plate was placed on ice, and 
the light treated cells were exposed to UV light (9 mW/cm2) for 20 minutes. Following the light 
exposure the plates were kept at room temperature for 100 minutes. Then, the cells were washed 
with sterile PBS and trypsinized. The trypsinized cells were centrifuged and resuspended in PBS 
supplemented with 10% FBS at 37oC and analyzed by flow cytometry. 
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3.3 Results: 
The transport of folates across cell membrane takes place by different receptors. Folate receptor α 
(FRα)90,91,92,80  is one such receptor that helps the transport of folates across the cell membrane by 
receptor mediated endocytosis. These FRα receptors are overexpressed in cancer cells. So many 
folate conjugated cytotoxins or radionuclitides have   targeted these FRα93,94 receptors to destroy 
the cancer cells. The drug that we have designed is a Dox-Folate conjugate which is believed to 
be taken up by these FRα folate receptors. In order to test for folate-receptor dependent uptake we 
needed cell lines with variable folate expression.  R2 cells are CHO cells where the -folate 
receptor has been knocked out whereas in the RT16 cells the folate receptors are over expressed. 
3.3.1 Effect of UV light on R2 and RT16 Cells  
The studies of the R2 and RT16 cells with the doxorubicin-folic acid drug conjugate would be 
carried out in the presence of UV light. It is important to see if the UV light has a role in causing 
cell death when these cell lines are exposed to the UV light over a certain interval of time. MTT 
assays were done with both R2 and RT16 cells where the cells were treated with media and 
exposed to UV light over an interval of (0-120) minutes regulated by an aluminum foil mask. The 
MTT assay was completed as mentioned in section 3.2.2.2.  The survival plots for R2 cells and 
RT16 cells have been shown in Figures 3.3.1 and 3.3.2 respectively. From the Figure 3.3.1 it is 
clear that the R2 cells have a high viability close to 80 % till 40th minute and after that there is a 
decrease in cell viability. For the RT16 cells the viability is close to 90% till the 80th minute and 
then there is a drop. Both these cell lines have a 100 % viability for the first 20 minutes. Thus 20 
minutes was chosen to be the time frame for the experiments to be conducted with the doxorubicin-
folic acid drug conjugate in order to avoid toxicity from the light. 
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Figure 3.3.1 Effect of UV Light on R2 cells: R2 cells were exposed to UV light over a time 
period of (0-120) minutes. 
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Figure 3.3.2 Effect of UV light on RT16 cells: RT16 cells were exposed to UV light over a time 
period of (0-120) minutes. 
 
 
 
 
 
 
 
 
 
 
 
0
20
40
60
80
100
120
140
160
180
0 20 40 60 80 100 120 140
%
  C
e
ll 
V
ia
b
ili
ty
 
Time (minutes)
 49 
 
3.3.2 FACS Studies  
3.3.3.1 Cell Permeability Studies in R2 and RT16 cells with and without Folic Acid in the 
dark 
   
We expected that folate receptor-null R2 cells would not show any uptake as they lack the folate 
receptors to promote the uptake of the drug whereas the RT16 cells will show the drug uptake due 
to the presence of the folate receptors.  In addition, we performed studies with and without folic 
acid to confirm receptor-dependent uptake at various time points (Figure 3.3.3).  These studies 
were performed in the dark in order to evaluate uptake prior to doing the release studies.  
The results of flow cytometry experiments for R2 cells at different time points and conditions have 
been shown in Figure 3.3.3. It clearly shows that neither doxorubicin alone nor Dox-Folate drug 
enters the R2 cells that lack the folate receptors. For the competition studies the cells were 
preincubated with folic acid for an hour prior to the addition of the Dox-Folate drug. In this study 
it was found that in presence of folic acid there seemed to be a slight increase in the uptake. The 
plot of % fluorescence at 24 hr time point with doxorubicin, Dox-folate drug conjugate and Dox-
folate drug conjugate with folic acid has been shown in Figure 3.3.4. 
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Figure 3.3.3 Histograms of R2 cells with doxorubicin, Dox-Folate + and – Folic Acid: 
Histograms of R2 cells only at t=30 mins (Panel A), with doxorubicin (1 µM) at t=30 mins, 3 hrs 
and 24 hrs from top to bottom (Panel B), with Dox-Folate conjugate (1 µM) at t =30 mins, 3 hrs 
and 24 hrs from top to bottom (Panel C) and with the Dox-Folate conjugate (1µM) + Folic acid 
(20µM, incubated for 1 hr with cells before adding the drug) at t=30mins, 3 hrs and 24 hrs from 
top to bottom (Panel D)  
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Figure 3.3. 4 Percentage Fluorescence Plot of R2 Cell: Plot of percentage fluorescence of 
doxorubicin, Dox-folate conjugate and Dox-folate conjugate with folic acid in R2 cells. 
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The flow cytometry experiments for RT16 cells at different time points and conditions have been 
shown in Figures 3.3.5 and 3.3.6. It clearly shows that both doxorubicin and Dox-Folate conjugate 
in the absence or presence of folic acid do not enter the RT16 cells even though they have 
overexpressed folate receptors. In the competition studies it was found that there was an increase 
in the uptake of Dox-Folate conjugate (Panel C of Figure 3.3.5) and of doxorubicin in the presence 
of folic acid (Panel B of Figure 3.3.6). It was necessary to do a control study where the cells were 
treated with only folic acid to see if that labels the cell. The study with just folic acid (Panel C of 
Figure 3.3.6) clearly shows that it does not label the RT16 cells that had the overexpressed folate 
receptors. The folic acid clearly blocks the folate receptors. The plot of % fluorescence at 24 hr 
time point with doxorubicin, Dox-folate drug conjugate and Dox-folate drug conjugate with folic 
acid has been shown in Figure 3.3.7. 
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Figure 3.3.5 Histograms of RT16 cells with doxorubicin, Dox-Folate + and –Folic Acid: 
Histograms of RT16 cells only at t=30 mins (Panel A), with doxorubicin (1 µM) at t=30 mins, 3 
hrs and 24 hrs from top to bottom (Panel B), with doxorubicin-folic acid drug conjugate (1 µM) at 
t =30 mins, 3 hrs and 24 hrs from top to bottom (Panel C) and with the Dox-Folate conjugate 
(1µM) + Folic acid (20µM, incubated for 1 hr with cells before adding the drug) at t=30mins, 3 
hrs and 24 hrs from top to bottom (Panel D)  
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Figure 3.3.6 Histograms of RT16 cells doxorubicin + Folic Acid, Folic Acid: Histograms of 
RT16 cells only at t=30 mins (Panel A), with doxorubicin (1 µM) + Folic acid (20µM, incubated 
for 1 hr with cells before adding doxorubicin) at t=30mins, 3 hrs and 24 hrs from top to bottom 
(Panel B) and with only folic acid (1µM) at t=30 mins, 3 hrs and 24 hrs from top to bottom (Panel 
C). 
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Figure 3.3. 7 Percentage Fluorescence Plot of RT16 Cells: Plot of percentage fluorescence of 
doxorubicin, Dox-folate conjugate and Dox-folate conjugate with folic acid in RT16 cells. 
  
0
10
20
30
40
50
60
70
80
90
100
Dox Cells+drug Cells +drug+FA
%
 F
lu
o
re
sc
en
ce
 56 
 
  
We do have an explanation as to why cell permeable doxorubicin did not accumulate in the cells.  
CHO cells are known to express P-glycoprotein 1 which is known to pump out doxorubicin as 
soon as it enters the cell. It is likely that the Dox-Folate drug conjugate also gets pumped out of 
both cell types. 
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3.3.3.2 Cell Permeability Studies in KB-3-1 cells with and without Folic Acid: 
 
Since our ultimate goal was to measure doxorubicin toxicity, we decided to change the cell line to 
KB-3-1 cells. These cells have overexpressed folate receptors and are expected to uptake the drug 
conjugate in the absence of folic acid.  
The fluorescence of doxorubicin was used to monitor the fluorescence and study the cell 
permeability via flow cytometry. From Figure 3.3.8 as expected the cells show a clear time 
dependent uptake of doxorubicin. The uptake of the Dox-Folate conjugate also increases with time 
as evident from panel C of Figure 3.3.8. But the inhibitory study did not give a satisfactory result. 
The panel D of this figure shows that even in presence of folic acid the drug conjugate is entering 
the cells which might indicate some different path of entry apart from the folate receptor for the 
drug. This is all the more clear from Figure 3.3.9 which clearly shows that the drug uptake in 
presence of folic acid (Panel C of Figure 3.3.9) is enhanced compared to experiments where cells 
are incubated alone with the Dox-Folate conjugate (Panel B of Figure 3.3.9).  The plot of % 
fluorescence at 24 hr time point with doxorubicin, doxorubicin folate conjugate with and without 
folic acid has been shown in Figure 3.3.8. 
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Figure 3.3.8 Histograms of KB-3-1 cells with doxorubicin ,  Dox-Folate +and – Folic Acid: 
Histograms of KB-3-1 cells only at t=30 mins (Panel A), with doxorubicin (1 µM) at t=30 mins, 4 
hrs and 9 hrs from top to bottom (Panel B), with doxorubicin-folic acid drug conjugate (1 µM) at 
t =30 mins, 4 hrs and 9 hrs from top to bottom (Panel C) and with the Dox-Folate conjugate (1µM) 
+ Folic acid (20µM, incubated for 1 hr with cells before adding the drug) at t=30mins, 4 hrs and 9 
hrs from top to bottom (Panel D)  
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Figure 3.3.9 Histograms of KB-3-1 cells with Dox-Folate , Dox-Folate + Folic acid: Histograms 
of KB-3-1 cells only at t=30 mins (Panel A), with Dox-Folate conjugate (1 µM) at t=30 mins, 4 
hrs, 9 hrs,12hrs and 24 hrs left to right (Panel B) and with the Dox-Folate conjugate (1µM) + Folic 
acid (20µM, incubated for 1 hr with cells before adding the drug) at t=30mins, 4 hrs, 9 hrs, 12 hrs 
and 24 hrs from left to right (Panel D)  
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Figure 3.3. 10 Percentage Fluorescence Plot of KB-3-1 Cells: Plot of   percentage fluorescence 
plot of doxorubicin, Dox-folate conjugate and Dox-folate conjugate with folic acid in KB-3-1 cells. 
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3.4: Discussion 
The FACS studies with the CHO cells showed no uptake of the drug due to the pumping out of 
doxorubicin by the P-gp pumps in these cells. The P-gp95,96,97, pumps expressed on these cell 
membranes identify foreign substances like drugs or toxins and pump them out of the cells using 
an ATP-dependent efflux pump. To avoid this issue, the cell line was changed to KB-3-1 cells. In 
these cell lines the drug was taken up by the cells but the inhibitory study in the presence of folic 
acid unexpectedly showed enhanced uptake of the drug. There could be various reasons for this. 
We surmise that pre-incubation of the cells with folic acid have activated endocytosis, pulling 
membrane bound-drug into the cells. The relatively slow uptake of the folate-dox conjugates 
suggests that this activation may be operative.  Alternatively, the pre-incubation with folic acid 
could have increased the folate receptor concentration on the cell surface to ultimately enhance 
uptake.  In either case, our inability to show selective blocking of uptake with folate led us to 
abandon these experiments. 
 
3.5 Future work  
Much of the work with folate inhibitors have been done with KB85b cells. So it may be fruitful to 
change the cell line to KB cells for further studies with the doxorubicin-folic acid drug conjugate.  
The other point that also needs to be addressed is the drug concentration used in the FACS studies. 
Most of the work done with these cell lines have folate conjugates added in nM range whereas we 
had used 1 µM. We used this high concentration in order to detect the penetration of the weakly 
fluorescent doxorubicin.  Using such a high concentration of the drug might have enhanced non-
specific binding that increased the drug uptake and obscured the folate specific update.  
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CHAPTER 4 
EFFECTS OF IODOACETAMIDE 
AZOBENZENE ON THE SECONDARY STRUCTURE OF 
PEPTIDES 
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4.1 Introduction  
The α-helix is an integral part of the secondary structure of proteins and it plays an important role 
in its biological function. Yet peptides excised from the a-helical domains of proteins typically do 
not retain their helical structure.  Many studies have been done to investigate the factors that 
stabilize and enhance α-helicity in peptides. The helicity could be stabilized by adding metal 
chelates, by introducing helix initiator templates or by using intramolecular peptide cross linkers 
98. Verdine and coworkers have developed hydrocarbon stapled peptides with improved helicity99. 
A ruthenium catalyzed olefin metathesis reaction takes place between the olefin side chains of the 
amino acids to form a hydrocarbon staple that improves the helicity of the peptides. Paramjit Arora 
and group have developed hydrogen bond surrogate helices where the intramolecular hydrogen 
bond is replaced by a C-C bond to form a better helix100. 
To have a spatial and temporal control over the secondary structure of peptides photoisomerizable 
linkers have been introduced to reversibly control the secondary structure of peptides. One of the 
most commonly used photoswitchable linker is azobenzene. Different derivatives of azobenzene 
have been used to control the secondary structure of peptides. Woolley and coworkers have used 
iodoacetamide, shown in figure 4.1.1 to improve the helicity of peptides 101. They have shown that 
this linker in its trans form when introduced at (i, i+7) residues of a peptide destabilizes the helicity 
as its length is too long to allow the adjacent residues to adopt an α-helical form. Whereas the 
length of the cis form of the linker is compatible with the (i, i+7) spacing and increases the helicity 
of the peptides and thus acts as an entropic helix stabilizer 102. The peptide with the trans form of 
the linker in the randomly coiled state when exposed to UV radiation changes to the more helical 
cis form as shown in Figure 4.1.2. The sequences on which most people have worked to study 
change in peptide helicity upon addition of linkers have been derived from the sequence 
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(EAAAR)n
103
 .The basic sequence (EAAAR)n is already helical due to the presence of ion pair 
interactions between glutamic acid (E) and arginine (R).   Therefore it is unclear how much 
contribution to the helicity is made by the azobenzene and how much is due to the intrinsic helicity 
of the peptide sequence itself. We reasoned that we could investigate the role of iodoacetamide 
azobenzene itself in affecting the secondary structure of peptides by systematically removing such 
ion pair interactions and by comparing the uncyclized to the azobenzene crosslinked peptides in 
each state. 
The initial sequence that we took for our study is Ac-EACARV1AACEAAARQ-NH2 where 1= 
α-amino isobutyric acid.  The peptide was cyclized and circular dichroism was used to measure 
the change in helicity upon cyclization under dark and light conditions.  We then systematically 
mutated the glutamic acids to arginine, to remove the ion pairs and replace them with the somewhat 
repulsive Arg-Arg pairs. A series of such peptides have been generated with different arginine 
mutations and cyclized with the iodoacetamide azobenzene linker. This study would give us an 
insight into the ability of the iodoacetamide linker itself to affect the secondary structure of 
peptides in the absence of helix promoting factors like ion-pair interactions. 
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Figure 4.1.1 4, 4/ Iodoacetamide Azobenzene 
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                         Figure 4.1.2 Conformational Control of Peptides by Azobenzene  
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4.2 Materials and Methods  
 
4.2.1 Synthesis of Linker 
The synthesis of the iodoacetamide linker was done based on the literature report43 . 4, 4/-
Diaminoazobenzene (225mg, 1.2 mmol) was dissolved in 20mL of anhydrous tetrahydrofuran. It 
was then stirred under argon for 15 mins and was protected from light during this time. Then 
triethylamine (3 equivalents, 500uL, 3.61 mmol) was added to the above solution followed by the 
dropwise addition of chloroacetyl chloride (3 equivalents, 287 µL, 3.61 mmol). The reaction was 
then stirred at room temperature for another 30 minutes and then vacuum filtration was done to 
remove the precipitate. The tetrahydrofuran was removed by rotary evaporation. The product 
obtained was dissolved in a 1:1 solution of tetrahydrofuran and dichloromethane and was extracted 
with water acidified with a few drops of 1% HCl. Anhydrous MgSO4 was use to dry the filtrate 
and it was then vacuum filtered. The solvents were then removed by rotary filtration to form 4, 4/-
Dichloroacetamide azobenzene. Then to form the iodo derivative from the chloro derivative at first 
a 20 mL solution of anhydrous acetone and 15 mL of anhydrous tetrahydrofuran were combined 
and degassed. 1 g (7.1 mmol) of sodium iodide was dissolved in the above degassed solvent and 
added to 150mg of dichloroacetamide acetamide. This solution was protected from light and was 
stirred for 12 hrs under argon. Sodium chloride was removed by filtration and the solvent were 
removed by rotary evaporation. The solid obtained was redissolved in a 1:1 solution of 
tetrahydrofuran and dichloromethane and vacuum filtration was used to remove excess of sodium 
iodide. The filtrate was extracted with water and anhydrous MgSO4 was used to dry it. It was 
vacuum filtered, the solvent was removed by rotary evaporation and a solid product of 4, 4/- 
iodoacetamide azobenzene was obtained. 
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4.2.2 Peptide Synthesis: 
Standard Fmoc-based solid phase peptide synthesis was used to make the peptides on a Liberty 
Automated Microwave Peptide Synthesizer (CEM). The peptides were made on a Fmoc-Rink 
amide MBHA Resin (0.65 mmol/gm). The formation of the peptides were confirmed by MALDI-
TOF and they were purified by reverse phase HPLC on a Shimadzu system with Vydac (218TP 
C18 5µ) column. The mobile phases used for the purifications were 0.1% TFA in water (A) and 
CH3CN (B) and they were monitored at 215nm.  The elution time for these purifications were 30 
minutes. The gradients used for the purification of the peptides and the mass obtained from the 
MALDI-TOF have been summarized in Table 4.2.1. 
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Table 4.2.1 Linear Peptides with HPLC gradient and MALDI-TOF values 
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4.2.3 Peptide Cross-Linking  
Peptide crosslinking with iodoacetamide azobenzene linker was performed according to a 
literature report.101 The uncrosslinked peptide (1.13 mM), Tris.Cl buffer (pH=8) and 
Triscarboxyethyl phosphine (1.13 mM) were combined in a volume of 355µL and stirred under 
Argon for 2 hrs to reduce the cysteine residues. To this a linker solution of 0.56 µmol in 500µL of 
DMSO was added and stirred in the dark for 10 min. A second aliquot of 10 mM solution of 55.8µL 
the linker was added to the solution and stirred in the dark for 10 min. Then a third aliquot of 10 
mM of the same volume of linker was added and stirred in dark for 10 minutes. This was s by an 
exposure of the solution to light for 20 minutes. The unreacted linker was removed by acetone 
precipitation. The cyclized peptides were purified using a Shimadzu system with Vydac (218TP 
C18 5µ) column using mobile phases 0.1% TFA in water (a) and CH3CN (B) and were monitored 
at 370 nm. The elution time for these purification was 30 minutes.  MALDI-TOF was used to 
confirm the formation of the cyclized peptides. The gradients used for the purification of the 
cyclized peptides and the mass obtained from MALDI-TOF has been summarized in table 4.2.2. 
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Table 4.2.2 Cyclized Peptides with HPLC gradient and MALDI-TOF values 
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4.2.4 Circular Dichroism 
Circular Dichroism was measured on an OLIS DCM 1000spectrophotometer. All measurements 
were done with a quartz cuvette of 0.1cm pathlength. The samples were dissolved in 5 mM of 
phosphate buffer of pH=7. The reported spectra are an average of 3 CD experiments. The response 
time was 4sec. response time. The mean residue weight of the peptide and cross-linked peptides 
were assumed to be the same for the respective peptides and were calculated by dividing the 
molecular weights of the peptides by the number of amino acid residues in the sequence. The 
peptide concentration was measured on a nanodrop ND 1000 spectrophotometer using a molar 
extinction coefficient of 28,000 for the iodoacetamide azobenzene linker in the dark state. 
 
 
4.2.5 Agadir Calculation 
The software Agadir (http://agadir.crg.es/) was used to calculate the percentage helicities of the 
uncyclized peptides. The conditions used for the calculations include a buffer concentration of 
5mM, temperature of 20oC and ionic strength of 0.03. 
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4.3 RESULTS  
4.3.1 Design of Azobenzene Linker 
The design of the azobenzene linker has been based on the work done by Andrew G. Woolley. The 
trans form of the linker is more stable than the cis form in the dark. In the paper (PNAS 2000, 8, 
3803) it has been shown that the iodoacetamide azobenzene linker when attached to the cysteine 
residues of the peptides at (i, i+7) positions disrupts and reduces its helicity. On shining light on 
the cyclized peptide in dark for 5 minutes the linker photoswitches to the cis form and in turn 
increases its helicity. We incorporated the azobenzene linker at the (i, i+7) positions of the peptides 
that we designed and studied the effect of the linker on its secondary structure upon 
photoisomerization. 
 
4.3.2 Design of Peptides  
We designed a series of peptides with varying number of arginines and studied the effect of the 
azobenzene linker on its secondary structure. The basic sequence used was Ac-
EACARV1AACEAAARQ-NH2 (Peptide R2) where 1=α-amino isobutyric acid (AiB) described 
by Woolley101. Molecular modeling had suggested that introduction of bulky amino acids at (i, 
i+3) and (i, i+4) positions between the linker attachment points would destabilize the trans 
conformation further. Thus the amino acids valine and AiB were introduced at the (i, i+3) and (i, 
i+4) positions with the purpose of creating steric interactions between these residues and the linker 
that would further destabilize the helicity of the peptides in the dark state. So upon 
photoisomerization of the linker a greater change in helicity is expected. A set of peptides were 
generated from this basic sequence by systematically replacing the glutamic acid with arginine to 
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replace the ion pairs with Arg-Arg repulsive pairs. The second sequence was obtained by replacing 
the glutamic acids in peptide R2 to generate the peptide R4 with 4 arginines as shown in the table 
4.3.1. Agadir software was used to generate the next set of peptides. It’s an algorithm based 
prediction which uses the helix coil transition theory. It predicts the helicity of monomeric peptides 
and takes into account factors such as pH, temperature, ionic strength, short range interactions and 
also terminal modifications of the peptides. The basic sequence of peptide R2 was used and 
arginine mutations were done to generate peptides with 6 and 8 arginines with the least helicity 
with the purpose of studying their change in helicity upon cyclization with the azobenzene linker. 
This led to the sequences of peptide R6 and R8 as shown in the table 4.3.1. The peptide R2 and 
R4 when extended by amino acids AAAR along the C terminus was found to have an increased 
helicity. This led to the generation of peptides R3 and R5 as shown in the table below. The 
sequences used for the studies have been summarized in Table 4.3.1. 
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Table 4.3.1 Peptide Sequence 
Peptide Sequences 
Ac-EACARV1AACEAAARQ-NH
2
            (Pep R2) 
Ac-RACARV1AACRAAARQ-NH
2
            (Pep R4) 
Ac-RACRRV1RACRAAARQ-NH
2
            (Pep R6) 
Ac-RACRRV1RACRARRRQ-NH
2
            (Pep R8) 
Ac-EACARV1AACEAAARAAARQ-NH
2
        (Pep R3) 
Ac-RACARV1AACRAAARAAARQ-NH
2
        (Pep R5) 
Where 1= α-Aminoisobutyric acid 
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4.3.3 Effect of the Photolinker on Secondary Structure of the Peptides  
The secondary structure of the peptides were measured using circular dichroism. At first the 
helicity of the uncylcized peptides were measured at 20oC as shown in Figure 4.3.1. Peptide R3 is 
the most helical among the six peptides with 21.2 % helicity and peptide R6 has the least helicity 
of  3.5 % as shown in Table: 4.3.2. The ion pair interaction between glutamic acid and arginine 
and the presence of an extra turn of the helix along the C terminus is responsible for the high 
helicity of peptide R3. The replacement of the ion pair interactions between glutamic acid and 
arginine with the arginine-arginine repulsive pairs reduce the helicity and thus accounts for the 
less helicity in peptides R4, R5, R6 and R8.  
The peptides were cyclized with the iodoacetamide linker. The circular dichroism of the cyclized 
peptides were measured in dark and then they were exposed to light at 370nm for 5 minutes and 
then the circular dichroism were again measured. The change in secondary structure of the linear 
peptides R2, R3, R4 and R5 upon cyclization has been shown in Figure 4.3.2. It is evident that 
there is not much change in helicity of peptide R2 upon cyclization as denoted by A in this figure. 
The helicity of R4 and R3 decreases upon cyclization as shown by B and C in this figure. On the 
other hand the helicity of R5 increases on cyclization. In peptide R4 in addition to the absence of 
the Glu-Arg ion-pair interaction the trans form of the linker further reduces its helicity. Whereas 
in peptide R3 the only destabilizing factor for the helicity is the trans form of the linker that reduces 
its helicity to 15.1 % from 21 %. In peptide R5 the repulsive interaction between the Arg-Arg 
residues is probably overcome to some extend by the trans linker that increases its helicity from 
8.2 % to 14.6 %.  
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Figure 4.3.1 CD of Linear Peptides: CD spectrum of Linear Peptides in 5mM Phosphate Buffer 
at pH=7 and 20o C. 
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Table 4.3. 2 Percentage Helicity of Linear and Cyclized Peptides 
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Figure 4.3.2 CD Spectrum of linear and Cyclized peptide R2 (A), R4 (B), R3 (C) and R5 (D) 
  
 80 
 
The changes in helicity of R2, R4, R3 and R5 peptides upon photoswitching of the linker from 
trans to cis form  has been shown in Figures 4.3.3. In each of these peptides the trans form of the 
linker changes to the cis form that is compatible with the (i, i+7) spacing and produces an increase 
in helicity. The greatest change in helicity is observed for peptide R5 which changes from 14.6 % 
to 38 %. This is followed by peptide R2 that changes from 13.2% to 34.1 %.  
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Figure 4.3.3 CD Spectra of Peptides R2 (A), R4 (B), R3 (C) and R5 (D) under light and Dark 
Conditions 
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4.4 DISCUSSION 
The effect of cyclization of the iodoacetamide azobenzene on the secondary structure of the 
peptides can be analyzed in the following categories. 
4.4.1 Effect of Arg-Glu Ion-pair Interaction and Length of Peptides 
In peptides R2 and R3 favorable Arg-Glu ion pair interactions exist. Upon cyclization the helicity 
of R2 does not change much whereas that of peptide R3 decreases. In peptide R3 there is an extra 
turn of helix along the C terminus where an additional Arg-Glu interaction exists. The azobenzene 
crosslinking position is at the cysteine adjacent to this Glu, and it is possible that a steric interaction 
disrupts this helix-stabilizing ion pair.  The opposite result is seen in peptide R5.  In this case, the 
cyclization linker appears to enhance helicity.  The trans form of the azobenzene is structurally 
incompatible with an alpha-helical conformation, so this enhancement is challenging to explain.  
We postulate that the cyclization helps to segregate the N-terminal repulsive arginines from the 
rest of the peptide by orienting them in a direction away from those in the C-terminus, enabling 
the C-terminal portion to adopt a more helical structure.   Thus we see that the degree of secondary 
structure present in any of these sequences is a very delicate balance of the existing ion-pair 
interactions, the length of the helix and the photoisomerization of the linker. In some cases the ion 
pair interaction overrides the cyclization while in other cases it’s the cyclization that overrides the 
ion pair interaction.  
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4.4.2 Dipole-Side Chain Interaction 
The helicity of a peptide also depends on the interaction between the peptide dipole and the side 
chain of the amino acids. It has been found that the positive side chain of arginine when present at 
the N terminus interacts with the dipole and destabilizes the α-helix and if it’s along the C terminus 
then it stabilizes it. In all these peptides there is an arginine at the C terminus. So the presence or 
absence of arginine along N terminus makes a contribution to its stability. In peptide R2 one 
arginine is at the C terminus and the other is at the center and upon cyclization not much change 
in its interaction with the dipole occurs and so the secondary structure does not change much. 
R4 has an arginine along the N terminus, 2 along the center and one at the C terminus. The arginine 
is almost equally distributed along the length of this peptide. Similar is the situation for peptide 
R5. So not much contribution to helicity is expected from this interaction. Upon cyclization 
probably the change in helicity observed in R4 and R5 is governed by other factors than this dipole 
–side interaction. Thus in these two peptides it’s the balance other factors like cyclization and Arg-
Glu interactions that finally determine the helicity. In R3 peptide the presence of two arginines 
along the C terminus makes it helical. Upon cyclization the helicity of this peptide decreases 
probably a change in alignment of the arginines reduces it interaction with the dipole and so a 
lesser % of helicity is obtained upon cyclization. 
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CHAPTER 5 
 PHOTOSWITCHABLE PEPTIDES - 
 IN TARGETED THERAPY  
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5.1 Introduction 
The chemotherapeutic treatment of cancer involves a variety of methods. The lack of specificity 
in the methods causes many side effects to the patients. In order to reduce these side effects and 
increase the specificity of the treatment the concept of targeted therapy has developed.  The 
molecular targets like human epidermal growth factor receptor 2 (HER-2) are identified and are 
treated with monoclonal antibodies Trastuzumab (Herceptin). Small molecular drugs like 
Dasatinib (Sprycel) are used which inhibit tyrosine kinase enzymes. Cancer vaccines are another 
means to treat cancer where; the vaccine activates a person’s immune system to recognize and 
attack the cancer cells. Another method of targeted therapy that is highly selective as well as 
specific is the light mediated treatment of cancer. Photodynamic therapy and photochemical 
internalization fall under this category. In photodynamic therapy74 phosensitizers trigger the 
formation of singlet oxygen upon irradiation with light of a suitable wavelength. It operates only 
in presence of light so it is highly selective. It has some drawbacks as the amount of molecular 
oxygen in cancer cells is often not very high. In photochemical internalization a toxin is at first 
internalized in cells in the endosome and this reduces the efficiency of the process. Both in 
photodynamic therapy and photochemical internalization there is much disparity in the light to 
drug administration time probably due to the slow uptake of the photosensitizers and formation of 
singlet oxygen. The method we have developed is devoid of the problems described above. A 
photoswitchable peptide is used which, in the dark state is randomly coiled and cell impermeable, 
but upon illumination becomes helical and cell permeable. Then upon entering the cell the drug 
attached to the peptide would be released causing cell death.   
The design of the peptides has been based on the work done by Woolley and co-workers.101 They 
have designed peptides and have used 4, 4/ - bis (iodoacetamide)-azobenzene to control the helicity 
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of these peptides. The linker when attached to the peptides through cysteines at (i, i +7) and (i, 
i+4) position in the trans form makes the peptide less helical as their end to end distance does not 
match the distance between the two cysteines. Upon exposure to UV radiation at 370 nm the trans 
isomer photoswitches to the cis form. In the cis form the end to end distance of the linker matches 
with the spacing between the two cysteines and this makes the peptides helical. To make the 
peptides more randomly coiled in the dark state they have introduced branched amino acids like α 
amino isobutyric acid (AiB) and valine at (i, i+3) and (i, i+4) positions between the cysteines which 
are seven amino acids apart. The linker in the trans form interacts sterically with these branched 
amino acids and further destabilizes the cyclized peptide in the dark state. Thus on 
photoisomerization a greater change in % helicity is observed. It has been established by Alanna 
Schepartz and group that an arginine patch developed on the helical surface of an impermeable 
protein makes it cell permeable.104,105 Based on these facts and the photoswitchable peptides 
designed by Woolley we have designed our peptides. We want the peptide to be randomly coiled 
in the dark state and change to a helical form in the presence of light. This will be possible when 
it is linked by a light sensitive linker at the (i, i+4) and (i, i+7) positions as established by molecular 
modeling studies51 done by Woolley and his co-workers. The linker that we will use to control the 
conformation of the peptide is 4, 4/ - bis (iodoacetamide)-azobenzene. In the trans form the peptide 
is randomly coiled and upon isomerization to cis form it would make the peptide helical as shown 
in Figure 4.1.2.   
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The initial sequence on which the work was started was Ac-2EACARV1AACEAAARQ-NH2 
where 2=Amidated cysteine and 1=α-amino isobutyric acid. To develop an arginine patch in this 
sequence the amino acids would be mutated to arginine. The formation of the arginine patch is 
clearly evident from the helical wheels in Figure 5.1.1 where replacement of the glutamic acids at 
position 2 and 12 with arginine generates an arginine patch as shown in helical wheel B. 
 
 
 
 
Figure 5.1.1 Helical Wheel of peptides 8.1 and 8.2: Helical Wheel of peptides Ac-
2EACARV1AACEAAARQ-NH2 (A) and Ac-2RACARV1AACRAAARQ-NH2 (B). 
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The amidated cysteine denoted as 2 in the peptide sequences would serve as an attachment point 
for the drug through a Cathepsin B cleavable linker. In the trans form of the linker the peptide with 
the drug would be cell impermeable. Upon illumination at 370 nm the linker would change to the 
cis form making the peptide helical with the arginines aligned together to form the arginine patch 
that would make it cell permeable. This has been shown in Figure 5.1.2. This system could 
potentially be used to deliver drugs into cells in the presence of light. 
 
 
 
 
Figure 5.1. 1 Light Induced Drug Delivery 
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5.2 Materials and Methods: 
5.2.1 Synthesis of Linker:  
The linker used is 4, 4/ - bis-iodoacetamide azobenzene and the synthesis has been done according 
to the literature report. The synthesis has been reported in details in the section 4.2.1. 
  
5.2.2. Peptide Synthesis: 
Standard Fmoc-based solid phase peptide synthesis was used to make the peptides on a Liberty 
Automated Microwave Peptide Synthesizer (CEM). The peptides were made on a Fmoc-Rink 
amide MBHA Resin (0.65 mmol/gm). The formation of the peptides were confirmed by MALDI-
TOF and they were purified by reverse phase HPLC on a Shimadzu system with Vydac (218TP 
C18 5µ) column. The mobile phases used for the purifications were 0.1% TFA in water (A) and 
CH3CN (B) and they were monitored at 215nm.  The elution time for these purifications were 30 
minutes. The HPLC chromatograms of the peptides and their mass spectra have been reported in 
the appendix section. 
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5.2.3 Peptide Cross Linking 
Peptide crosslinking with the iodoacetamide azobenzene linker has been done as mentioned in 
section 4.2.3. The cyclized peptides were purified using a Shimadzu system with Vydac (218TP 
C18 5µ) column using mobile phases 0.1% TFA in water (a) and CH3CN (B) and were monitored 
at 370 nm. The elution time for these purification was 30 minutes.  MALDI-TOF was used to 
confirm the formation of the cyclized peptides. The chromatograms for the purification of the 
cyclized peptides and their mass spectra have been reported in the appendix. 
 
 
5.2.4 Circular Dichroism 
Circular Dichroism was measured on an OLIS DSM 1000 spectrophotometer. All measurements 
were done with a quartz cuvette of 0.1cm pathlength. The samples were dissolved in 5 mM of 
phosphate buffer of pH=7. The reported spectra are an average of 3 CD experiments. The response 
time of the instrument was 4 second. The mean residue weight of the peptide and cross-linked 
peptides were assumed to be the same for the respective peptides and were calculated by dividing 
the molecular weights of the peptides by the number of amino acid residues in the sequence. The 
peptide concentration was measured on a nanodrop ND 1000 spectrophotometer using a molar 
extinction coefficient of 28,000 for the iodoacetamide azobenzene linker in the dark state at 367 
nm. 
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5.2.5 Removal of Acm group of Amidated Cysteine 
The amidated peptide (22mg, 3µmol) was treated with TFA containing 1 % of anisole. To this 
solution Ag2SO4 (80mg, 480µmol) was added and was stirred at 4
oC for 2 hours. Then the solution 
was concentrated under argon. Around 5mL of cold ether was used to precipitate the peptide from 
the above concentrated solution. The concentrated solution was vortexed and centrifuged. The 
precipitated peptide was treated with 1 mL of dithiothreitol (0.2M in 1M acetic acid) for 3 hours 
at room temperature. After 3 hrs this solution was filtered and injected on HPLC. The purified 
peptide obtained from HPLC was then subjected to mass spectra analysis to confirm the removal 
of the acm group. The mass spectra and HPLC traces of peptide 8.5 are there in the appendix. 
 
 
5.2.6 FAM5 Labelling of Peptides  
The peptides were labelled with 5(6) Carboxyfluorescein (Fam-5) [shown in Figure 5.2.1]. The 
labelling of the peptide was done on the resin. on which the peptide was synthesized. Fam-5 (0.3 
mmoles, 112.8 mg) was dissolved in 4 mL of N, N-dimethyl formamide (DMF). It was covered in 
aluminum foil and put on a tumbler for 20 minutes that would help in the dissolution of Fam-5 in 
DMF. Then this Fam-5 solution was added to a tube containing the peptide-resin (0.01 mmoles, 
27 mg). To this was added a solution of N, N-dicyclohexylcarbodiimide [DCC] (0.3 mmoles, 61.9 
mg) dissolved in 200 µL of DMF and hydroxybenzotriazole [HOBT] (0.3 mmoles, 40.5 mg) 
dissolved in 200 µL of DMF. The tube with all these contents was covered with aluminium foil 
and kept on a tumbler overnight to complete the labelling of the peptide. The formation of the 
labelled peptide was confirmed with Ninhydrin test. In this test some of the beads are taken in a 
small test tube and washed with DMF, MeOH and DCM thoroughly. Then they were washed 3-4 
 92 
 
times with ethanol. Then a few drops of Kaiser solution A [20 µL KCN (13 mg dissolved in 20 
mL of water) with 980 µL of pyridine and to this was added 100 µL of Pyridine/ethanol solution 
(8g of phenol in 2 mL of absolute ethanol)] and Kaiser solution B [1.0 g of Ninhydrin in 20 mL of 
absolute alcohol] was added. The tube was kept in a heating block at 100o C for 2 minutes. The 
color of the beads were observed. The color of the beads remain yellow indicating they were 
labelled with Fam-5. If the color of the bead changed to blue then that would indicate the presence 
of free amine that had reacted with Ninhydrin to form the blue compound Ruhemanns blue. The 
labelling method has been summarized in Figure 5.2.2. 
  
 
 
 
 
Figure 5.2.1 Structure of 5(6)-Carboxyfluorescein 
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Figure 5.2. 2 Labelling of Peptide with 5(6)-Carboxyfluorescein (FAM5)  
 
 
5.2.7 Cell Studies  
The Esophageal cancer cell line (JH-EsoAd1) was cultured at 37oC and in a humidified atmosphere 
of 5% CO2 in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS). For 96 well 
plate experiments, the JH-EsoAd1 cells were seeded at 4450 cells/well in 100uL of media in 96 
well plates; experiments were carried out one day after seeding. MTT assays were analyzed using 
a Bio-Tex µQuant plate reader at 562 nm. FACS was performed BD FACS Aria II using BD FACS 
Diva software at the VCU Flow Cytometry Core Facility. A minimum of 20,000 cells within the 
gated region were analyzed. Confocal microscopy images were acquired at room temperature with 
a Leica confocal laser scanning microscope. 
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5.2.7.1 Fluorescence Microscopy  
The cell permeability of the cyclized labelled peptide was studied initially using fluorescence 
microscopy. Fam-5 Labelled Arg-9 peptide was used as a positive control as it is known to be 
highly cell permeable. Olympus inverted Fluorescence microscope was used for these 
experiments.  
To determine the concentration of Arg9 needed to label the cells around 30,000 cells were plated 
in a 3mm sterile cell culture plate. The following day the cells were treated with Arg9Fam5 peptide 
at concentrations of   0.09 µM, 0.18 µM, 0.37 µM, 0.75 µM, 1.5 µM and 3 µM. The peptide was 
incubated with the cells for an hour. Then the media was removed and the cells were washed with 
PBS (3x) and fresh media was added. The plates were then observed under the fluorescence 
microscope. The minimum concentration of Arg9Fam5 needed to label 
JH-EsoAd1 cells were seeded at 5000 cells/well and treated with media alone, Fam-5 labelled 
Arg9 (Arg9Fam5) peptide and Fam-5 labeled cyclized peptides in a 96 well clear-bottom, opaque 
plate under light and dark conditions. Cells were exposed to light (9 mW/cm2) for various times 
(0-40 min) regulated by an aluminum foil mask. During the experiment, the plate was kept in ice 
to reduce the heating by the UV lamp.  After the lamp was turned off, the plate was covered with 
foil and placed at room temperature for an additional 80 min. The media was removed, and the 
cells were thoroughly washed with PBS (3x); then 200 µL of fresh media was added to each well. 
The plates were then observed under the fluorescence microscope to check the permeability of 
Arg9 and Fam-5 labeled cyclized peptide. 
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5.2.7.2: Flow Cytometry Analysis for Cell Permeability:  
JH-EsoAd1 cells were seeded at 200,000 cells/well in 1.5 mL of media in 6 well plates. The cells 
were treated with media alone or media supplemented with Arg9Fam5 or Fam-5 labeled cyclized 
peptides. The plate was placed on ice, and the light treated cells were exposed to UV light (9 
mW/cm2) for 20 minutes. Following the light exposure the plates were kept at room temperature 
for 100 minutes. Then, the cells were washed with sterile PBS and trypsinized, centrifuged and 
resuspended in resuspended in PBS and analyzed by flow cytometry. 
 
 
5.3: Results: 
5.3.1: Design of peptides: 
The peptide sequence on which Woolley has studied the effect of photoswitching with 
iodoacetamide linker is Pep 8 of Table 5.3.1. In this peptide the cysteines are at (i, i+7) spacing. 
Based on this sequence a peptides 8.1 and 8.2 (shown in Table 5.3.1) were designed where arginine 
mutations were introduced to develop peptides with an arginine patch that would eventually help 
in their cell permeability. We also wanted to explore the effect of the iodoacetamide azobenzene 
on the helicity of the peptide when attached at (i, i+4) positions and so Pep 8.3 was synthesized. 
The peptides 8.1, 8.2 and 8.3 were cyclized and then the CD data was obtained. The problem 
encountered during the purification of these cyclized peptide was their extremely low yield. The 
amount of peptides obtained after the removal of Acm protecting group of amidated cysteine was 
extremely low. To improve the yield of the peptides it was decided to label them with a fluorescent 
tag. The fluorescent tag Fluorescein-5-isothiocyanate (FITC) was added at the N terminus to form 
Pep 8.4. During the cyclization of this peptide the resulting thiourea competed with the other two 
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cysteines to react with the linker and thus the expected cyclized peptide was not obtained. The 
sequences were further changed to Peptides 8.5 and 8.6 where FAM-5 was used as a fluorescent 
label. They were cyclized and purified and a good yield was obtained. The cell permeability of 
these two peptides were studied using Jh-EsoAd1 cells. 
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Table 5.3. 1 Peptide Sequences 
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5.3.2 Effect of Linker on Helicity of Peptides 
The secondary structure of the cyclized peptides was measured using circular dichroism in before 
and after irradiating with 370 nm light for 5 min. 
 
5.3.2.1 Change in Helicity of Peptides with Linker attached at (i, i+7) and (i, i+4) position 
 
 We were interested to see how the iodoacetamide azobenzene linker would change the helicity of 
peptides when attached at a (i, i+7) and (i, i+4) positions. The CD spectrum of peptides 8.1, 8.2 
and 8.3 were recorded in the dark, after irradiation with UV light for 5 minutes and 30 minutes 
after removal of light.  The spectrum showed that the change in % helicity of peptides 8.1 and 8.2 
with cysteines at (i, i+7) positions were higher than that of pep 8.3. So it was decided to pursue 
further studies with peptides attached to the linker at (i, i+7) positions. Among peptides 8.1 and 
8.2 a greater change in % helicity was observed for pep 8.3. The CD spectrum of peptides 8.1and 
8.2 have been shown in Figures 5.3.1 and 5.3.2. The change in helicity for both peptides have been 
shown in Table 5.3.2.  
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Figure 5.3.1 CD Spectrum of  Pep 8.1: CD Spectrum of Ac-2EACARV1AACEAAARQ-NH2 
(Pep 8.1) in phosphate buffer at pH=7  
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Figure 5.3.2 CD Spectrum of Pep 8.2: CD Spectrum of Ac-2RACARV1AACRAAARQ-NH2 
(Pep 8.2) in phosphate buffer at pH=7 
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Table 5.3. 2 Percent Helicity of Peptides 8.1 and 8.2 
 
 
5.3.2.2 CD Spectrum of Pep 8.2 at 25oC and 37oC 
The permeability of the peptides would eventually be studied in cells at 37oC and hence it was 
necessary to see how the helicity of the peptides change at this temperature. The CD spectrum of 
peptide 8.2 was measured at 25oC (Figure 5.3.3) and 37oC (Figure 5.3.4). The measurements were 
done in dark, immediately after shining light for 5 minutes and readings were taken for about an 
hour since the light was removed.  It was found that the helicity change was greater at 25oC than 
at 37oC. The % change in helicity of pep 8.2 at 25oC and  37oC has been shown in Table 5.3.3 
and 5.3.4 respectively. With the rise in temperature the kinetic energy of the molecules increase 
which leads to their unfolding. As the temperature increases from 25oC to 37oC the peptide 8.2  
unfolds and so the helicity also reduces. Since the helicity is low at 37oC not much change in it is 
observed on exposure to UV radiation when the linker photoswitches. These studies indicate that 
to attain a decent amount of change in % helicity at 37oC the peptide sequence needs to be 
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modified. The simultaneous low yield of Pep8.2 also led to change the sequence to pep 8.5 and 
8.6. Further CD studies would be done with these peptides. 
The CD of the Fam-5 labelled cyclized Pep 8.5 gave a percentage helicity of 250.2 in dark to 
266.3% upon illumination. Literature search showed that researchers working with Fam-5 labelled 
peptides took the CD of the unlabeled peptides while they used the Fam-5 labelled peptide for cell 
studies. Fam5 probably might interfere with the CD measurement and hence such numbers of % 
helicity were obtained. 
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Figure 5.3.3 CD spectrum of Pep 8.2 at 25oC: CD spectrum of Ac-2RACARV1AACRAAARQ-
NH2 (Pep 8.2) at 25
o C in phosphate buffer at pH=7 
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Table 5.3.3 Percent Helicity of Peptide 8.2 at 25oC 
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Figure 5.3.4 CD Spectrum of Pep 8.2 at 37oC: CD Spectrum of Ac-2RACARV1AACRAAARQ-
NH2 (Pep 8.2) at 37
o C in phosphate buffer at pH=7 
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Table 5.3.4 Percent Helicity of Peptide 8.2 at 37oC 
 
 
 
5.3.3 Measurement of Half Life of Cyclized pep 8.2 
The Half-life of the azobenzene linker in cyclized peptide 8.2 was determined using HPLC. At 
first the cyclized pep 8.2 was exposed to UV radiation at 370nm for 5 minutes. Small volumes 
were removed at various times for direct analysis by HPLC. At the beginning when t=0 there were 
two peaks denoting the presence of both the cis and trans form of the cyclized peptide 8.2. As time 
increased from 32 mins to 96 mins one of the peaks decreased indicating that the cis isomer was 
thermally relaxing back to the trans isomer. The half-life was determined to be 50.58 minutes using 
the plot shown in Figure 5.3.6. 
Half-life was calculated using the equation y=Ae-KT where y= quantity at time t, A= quantity at 
t=0, k=decay constant.   
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Figure 5.3.5 Chromatograms for Cyclized pep 8.2: Chromatograms for Cyclized pep 8.2 at 
1=0mins, 2=32mins, 3= 64 mins and 4=96mins. 
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Figure 5.3.6 Half-life of cyclized peptide 8.2: Plot of % Cis isomer of cyclized peptide 8.2 with 
time to calculate half-life of cyclized peptide 8.2 
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5.3.4: Fluorescence Microscopy to Study Peptide Permeability  
5.3.4.1 Concentration Dependent Permeability Study of Arg9Fam5 
A concentration based permeability study of the control peptide Arg9Fam5 in JH-EsoAd1 cells 
was done using fluorescence microscopy. The plates were then observed under the fluorescence 
microscope. The minimum concentration of Arg9Fam5 needed to label the Jh-EsoAd1 cells was 
1.5 µM as evident from Figure 5.3.7.  
 
 
 
 
Figure 5.3.7 Concentration dependent study of Arg9Fam5 with Jhe-EsoAd1 cells 
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5.3.4.2: Permeability Study of Fam-5 labeled Peptides 
A permeability study of the Fam-5 labeled Pep 8.5, Pep 8.6, control peptide Arg9Fam5 and 
negative control Fam5 was performed on JH-EsoAd1 cells. The concentration of all the peptides 
used in the assay was 1.5µM. Only the cells treated with Arg9Fam5 both under light and dark 
conditions were labelled as evident from Figure 5.3.8. The Fam5 labelled peptides Pep 8.5, Pep 
8.6 and Fam5 itself did not label the peptides. As a concentration of 1.5µM of the labeled peptides 
was used for these studies it could be possible that a little higher concentration these labeled 
peptides are permeable. To validate these results flow cytometry studies were performed on JH-
EsoAd1 cells with the lab labeled peptides at a higher concentration. 
 
 
 
Figure 5.3.8 Fluorescence Microscopy studies with FAM5 labelled peptides: Cell Permeability 
study of Fam5 labelled Pep7, Pep8, Arg9Fam5 and Fam5 at concentration of 1.5µM 
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5.3.4.3 Flow Cytometry Study of labelled Peptides 
To study the permeability of the Fam5 labelled peptides JH-EsoAd1 cells were plated at 150000 
cells/well in 6 well cell culture plates. The Cells were treated with only media, media supplemented 
with Arg9Fam5 (1.5 µM), Pep 8.6 (Fam5-RACARV1AACRAAARQ-NH2, 40uM and 76 uM) 
under dark and light conditions. For the experiments with light the cells were exposed to UV light 
for 20 minutes and then were kept in dark for 100 minutes. The media was removed, cells were 
washed with PBS (3x), trypsinized and then suspended in PBS for flow cytometry. 
The cells were labelled extensively with ARg9Fam5 at 1.5 uM of the peptide used. On the other 
hand a large amount of Pep 8.6 was used for the studies to get a sufficient amount of labelling. 
From Figure 5.3.9 it is evident that there is not much difference under light and dark conditions 
for Pep 8.6. As per our hypothesis it was expected that the Pep 8.6 under dark condition would not 
label the cells whereas upon illumination as the linker would change to the cis form the peptide 
would become helical and cell permeable. But the results obtained were contrary to our 
hypothesis—the peptide was not cell permeable under either conditions. 
The reason that not much difference in the light and dark condition is observed is probably because 
of the peptide’s poor % change in helicity at 37 degrees.  
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Figure 5.3. 9 Histogram of JH-EsoAd1 cells with FAM5-Pep8 and FAM5Arg9: Histograms 
of JH-EsoAd1 cells only and with Arg9Fam5 at 1.5 µM from top to bottom of Panel A, with Pep8 
(40µM) under Dark (top) and Light (bottom) of Panel B, with Pep8 (76µM) under Dark (top) and 
light (bottom) of Panel C  
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5.3.5 CD Studies of Peptides developed from Computational Studies 
5.3.5.1 Computational Studies to Generate Peptide Sequences 
Computational studies were done in collaboration with Prof. Glenn Kellogg’s lab to develop a 
series of peptides that would show some change in helicity when cyclized with meta-dibromo 
xylene linker. They built peptide sequences within SYBYL-X in α-helical conformation using 
charged termini and using the sequence of peptide 5 as the basic sequence as shown in Table 5.3.5. 
The other sequences were obtained by replacing alanine with AiB (α-amino isobutyric acid)106 as 
AiB is a helix promoter. A total combination of 91 sequences were obtained using all possible 
combinations by incorporating a maximum of four AiB amino acids. They were then subjected to 
minimization studies under TRIPOS force field. 10 sequences were selected out of this pool to do 
molecular dynamics simulation studies to predict their secondary structure. Finally a total of four 
peptides were selected for CD studies from this set of 10 peptides as shown in Table 5.3.5.   
 
Table 5.3. 5 Peptide Sequences from Computational Studies 
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5.3.5.2 CD Studies of Peptides with AiB Mutations 
The CD spectrum of the linear peptides obtained from computational studies clearly showed that 
these peptides had a very low helicity. This has been shown in Figure 5.3.10. The percentage 
helicity of the peptides were very low as shown in Table 5.3.6.  
 
 
 
 
Figure 5.3. 10 CD of Peptides 5.5.1, 5.2 and 5.3: CD Spectrum of Peptides 5, 5.1, 5.2 and 5.3 in 
phosphate buffer at 20oC in phosphate buffer. 
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Table 5.3. 6 Percentage Helicity of Peptides 5, 5.1, 5.2 and 5.3 
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5.4 Discussion  
The cell permeability studies clearly indicated that cyclized peptides were not cell permeable both 
under dark and light conditions. The CD studies clearly showed that peptides had low helicity at 
37oC. There are certain factors that needs to be modified in order to improve the helicity of the 
peptides. The peptide lengths and nature of amino acids in the sequences can be modified. It is 
also possible that the peptides had less amount of arginines in it. So if the sequence of peptide 8.5 
which is Fam5-EACARV1AACEAAARQ-NH2 can be modified by introducing more arginines at 
different positions and tested for cell permeability then some promising result might be obtained. 
A series of such peptides have been developed as shown in chapter 4 and they need to be tested 
for cell studies. Simultaneously computational studies with the basic peptide 5 with different AiB 
substitutions generated a total of 4 peptides and the CD studies also showed that these peptides 
had very less helicity. Computational studies with peptide 8 where the N terminus would have an 
acetyl and the C terminus would have an amide and with arginines at different positions might 
generate a series of peptides. The CD study with this set of peptides might give some new results. 
 
 
5.5 Future Work 
The basic peptide 8.5 would be mutated with arginines at various positions and labelled with Fam5 
and used for cell studies on Jh-EsoAd1 cells both under light and dark conditions. At the same 
time computational studies would also help to decide on the sequences of peptides to be used.  
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5.6 Summary 
In the first part of this thesis we have discussed the development of a new strategy called 
photocaged permeability (PCP). Using this strategy we have shown the light controlled release of 
doxorubicin in the esophageal adenocarcinoma cell lines. The concept of photocaged permeability 
has been further developed to introduce dual specificity in the drug delivery systems. The dox-
photocage would be attached to a molecule that is specific for a receptor overexpressed on the cell 
surface. Thus attachment to a specific receptor and the release of doxorubicin from the internalized 
drug upon exposure to radiation would make the process dually specific. Folic acid has been 
attached to the photocaged doxorubicin to specifically target the overexpressed folate receptors on 
the cancer cells. The photocaged doxorubicin would be further attached to different chemical 
substances that are specific for other receptors overexpressed in cancer cells. 
In later part of the thesis we talk about a series of designed peptides whose conformation was 
controlled by the photoswitch iodoacetamide azobenzene. The secondary structure of these 
peptides changed upon cyclization but did not show much cell permeability. So a new series of 
peptides with different number of arginine substitutions have been developed and they would be 
tested for cell permeability. Computational studies would also be done to generate a series of 
cyclized peptides that might possibly show more permeability upon exposure to radiation. 
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